271 related articles for article (PubMed ID: 28767462)
1. Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection.
Babatin MA; Alghamdi AS; Albenmousa A; Alaseeri A; Aljarodi M; Albiladi H; Alsahafi A; Almugharbal M; Alothmani HS; Sanai FM; Bzeizi KI
J Clin Gastroenterol; 2018; 52(5):452-457. PubMed ID: 28767462
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Gaeta GB; Aghemo A; Menzaghi B; D'Offizi G; Giorgini A; Hasson H; Brancaccio G; Palma M; Termini R;
Medicine (Baltimore); 2018 Jul; 97(27):e11307. PubMed ID: 29979400
[TBL] [Abstract][Full Text] [Related]
4. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
Pott-Junior H; Bricks G; Grandi G; Figueiredo Senise J; Castelo Filho A
Clin Microbiol Infect; 2019 Mar; 25(3):365-371. PubMed ID: 29906601
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
8. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Omar H; El Akel W; Elbaz T; El Kassas M; Elsaeed K; El Shazly H; Said M; Yousif M; Gomaa AA; Nasr A; AbdAllah M; Korany M; Ismail SA; Shaker MK; Doss W; Esmat G; Waked I; El Shazly Y
Aliment Pharmacol Ther; 2018 Feb; 47(3):421-431. PubMed ID: 29193226
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Pellicelli AM; Pace Palitti V; Vignally P; Ceccherini-Silberstein F; Siciliano M; Giannelli V; Moretti A; Tarquini P; Scifo G; Messina V; Ascione A; Izzi A; Marignani M; D'Ambrosio C; Fondacaro L; Ettorre GM; Ialongo P; Sacco R; Perno CF; Barbarini G;
Liver Int; 2017 May; 37(5):653-661. PubMed ID: 27782373
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2019 Sep; 82(9):693-698. PubMed ID: 31356562
[TBL] [Abstract][Full Text] [Related]
13. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
14. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM
Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792
[TBL] [Abstract][Full Text] [Related]
15. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Gut; 2016 Nov; 65(11):1861-1870. PubMed ID: 27605539
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Bruno G; Saracino A; Fabrizio C; Scudeller L; Milano E; Dell'Acqua R; Ladisa N; Fasano M; Minniti S; Buccoliero G; Tartaglia A; Giammario A; Milella M; Angarano G
Int J Antimicrob Agents; 2017 Mar; 49(3):296-301. PubMed ID: 28163136
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
